PCI acquires Bellwyck Pharma Services

By Jenni Spinner

- Last updated on GMT

(Image: Getty/Manop1984)
(Image: Getty/Manop1984)

Related tags: Pci pharma services, Bellwyck Pharma Services, primary packaging, Secondary packaging

The purchase follows PCI’s plans to expand its clinical trial services globally, including in North America and Europe.

Headquartered in Toronto, Canada, Bellwyck focuses on primary and secondary packaging and labeling for the clinical trial and commercial drug markets. Its acquisition expands PCI Pharma Services’ network of good manufacturing practice (GMP)-compliant facilities by four.

Salim Haffar, PCI’s CEO, told Outsourcing-Pharma that the company’s recent string of acquisitions fits its goal to expand its global presence and provide greater access for customers.

Our recent acquisitions align with our purpose to be the bridge between life-changing therapies and patients around the world, helping us achieve greater access around the world for our clients.

“With the addition of Bellwyck, PCI has now established a presence in Canada and Germany, ranked third and fourth in the world for total number of clinical trials, respectively, extending the reach of PCI’s clinical services in key markets,” he said.

The clinical and commercial supply chain solutions offered by Bellwyck support PCI’s core capabilities, such as clinical trial packaging, labeling and logistics for Phase I-IV studies, and full-service commercial packaging, the company stated. The acquisition brings the number of PCI’s GMP-compliant facilities to 25 and increases its total workforce in North America, Europe and the Asia-Pacific region to more than 3,700.

The addition of Bellwyck will mark PCI’s third acquisition outside of the US in three years, demonstrating its focus on geographic expansion.

The company in August 2019 announced plans to construct a 75,000-square-foot dedicated clinical facility outside of Dublin​, Ireland. Additionally, in February 2018, the company declared its intentions to snap up Melbourne, Australia-based Pharmaceutical Packaging Professionals​.

Haffar told Outsourcing-Pharma that PCI continues to hunt for strategic acquisitions around the globe.

We are always on the lookout for partnerships that complement our capabilities and allow us to enter new markets; we will continue our strategy to ensure we are servicing our clients and the patients they serve in the best way possible,” he said.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 18-Jul-2022 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

Planning Your First-In-Human Trial

Planning Your First-In-Human Trial

Altasciences | 15-Jul-2022 | Technical / White Paper

A first-in-human (FIH) clinical trial is a significant milestone in the development of a potential new drug. A successfully conducted FIH trial provides...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 13-Jul-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers

Follow us

Products

View more

Webinars